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control at 12m was 48.4%. The median survival time was 30.9 
m for all patients. Delayed whole brain radiotherapy was 
needed in 13 patients. Applying univariate analysis no 
differences were observed either in BM volume, type of 
primary tumor, radiation doses, RPA and GPA indexes or time 
of presentation (synchronous vs. metachronous BM). One case 
of confirmed radiation necrosis was observed. 
Conclusions: Adjuvant RT after BM excision is safe, feasible 
and might avoid whole brain radiotherapy in a significant 
percentage of patients. We have not found differences 
between synchronous vs. metachronous presentation. 
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Purpose/Objective: Whole Lung Irradiation (WLI) is an option 
for pediatric Ewing Sarcoma (ES) with pulmonary metastases 
(PM) at time of diagnosis. At our institution, patients with 
Ewing's Sarcoma (ES) and PM at time of diagnosis are treated 
with WLI. The aim of this study was to analyze feasibility, 
overall survival and disease free survival in a homogeneous 
population.  
Materials and Methods: Seventeen patients were included in 
this retrospective, monocentric study. All patients underwent 
a local therapy on the site of primary tumor (surgery and/or 
radiation therapy) and a systemic treatment with induction 
chemotherapy (Vincristin, Adriamicin, Ifosfamide and 
Etoposide). Patients whose pulmonary metastases not 
responded at induction chemotherapy were 5 (29.4%), and 
underwent surgical resection of PM. All patients underwent 
systemic consolidation treatment with HDCT (Busulfan plus 
Melphalan) followed by WLI, that was administered by three 
dimensional (3D) conformal radiation therapy at dose of 15 
Gy in 10 fractions (fr) (in patients > 12 years old) or 12 Gy in 
10/fr (in pediatric patients). Patients demographics, fields of 
irradiation, local treatment and systemic treatment were 
collected. All patients were evaluated by clinical and 
radiological exams during the follow up. Duration of survival 
was defined as the time interval between diagnosis and death 
from any cause or most recent follow-up visit. Duration of 
disease free survival was defined as the time interval 
between diagnosis and disease recurrence or progression, 
death or most recent follow-up visit. 
Results: Mean age at time of diagnosis was 16.1 years (range 
7-34). The mean follow up time of surviving patients was 34.9 
months (range 10-84). The rate of pulmonary relapse (PR) 
was 52%. At 12, 24 and 36 months, DFS was 80.7%, 53.8% and 
40.3% and OS was 100%, 78% and 54.5%. Younger patients (< 
16 years old) had a higher survival (at 12, 24 and 36 months: 
100%, 100%, 85% vs 100%, 53.6 and 17.9%, respectively; 
p=0.005; Figure). Radiation pneumonitis developed in three 
patients at a median of 3 month (2,3,4 months) after WLI and 
was successfully treated with steroids. No clinically evident 
deterioration in pulmonary function was detected.  
 
Conclusions: Bilateral whole lung irradiation is a simple 
procedure with few acute or late sequelae. Our finding 
showed that pediatric patients had a higher survival. Further 
trials are necessary to define the WLI role in adults. 
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Purpose/Objective: Studies in advanced Hodgkin lymphoma 
(HL) suggest many relapses occur at the sites of initial 
disease, and have been used to justify the use of 
consolidative radiotherapy (RT). However, the chemotherapy 
regimens used in these studies vary from current practice and 
positron emission tomography (PET) was not used for 
assessment of stage or response. The aim of this study is to 
characterise patterns of relapse and survival outcomes in 
patients with PET staged advanced HL treated with the 
chemotherapy regimen of doxorubicin, bleomycin, vinblastine 
and dacarbazine (ABVD). 
Materials and Methods: Patients over 18 years old with 
newly diagnosed Stage III or IV HL treated with ABVD 
chemotherapy at our institution from January 2005 to 
December 2012 were included in this study. All patients were 
evaluated with PET prior to chemotherapy for staging and 
following chemotherapy to assess response. Patients were 
given consolidative RT at the discretion of treating clinicians. 
Patterns of relapse, disease-free survival (DFS) (measured 
from attainment of a complete response (CR) to disease 
recurrence or death), progression-free survival (PFS) 
(measured from first day of chemotherapy to lymphoma 
progression or death) and overall survival (OS) (measured 
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from first day of chemotherapy to death of any cause) were 
evaluated. 
Results: A total of 43 patients were included. The median 
follow-up was 45 months (range 6-105 months). Five year 
DFS, PFS and OS were 90%, 76% and 86% respectively. On 
post-chemotherapy PET, CR was seen in 35 patients (81%), 
partial response in three patients (7%) and progression in five 
patients (12%).  
Of the patients with CR, three patients (9%) relapsed, all in 
initial sites of disease with one patient also relapsing in new 
sites. Three of four patients with bulky disease (defined as a 
single nodal mass of 10cm or greater) received consolidative 
RT and none of these patients relapsed. Five year OS for 
patients with PET CR was 94%. Two patients died, one from 
progressive disease and one from bleomycin-related lung 
toxicity. 
Conclusions: Advanced stage HL with PET CR following ABVD 
chemotherapy is associated with an excellent prognosis. 
Relapses were low and occurred in both initial and new sites. 
The use of consolidative RT for bulky disease provided good 
disease control, with no relapses observed.  
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Purpose/Objective: Stereotactic radiosurgery (SRS) is an 
alternative to post-operative whole brain radiation therapy 
(WBRT) following resection of brain metastases. At our 
institution, CyberKnife (CK) is generally used for local 
treatment of larger cavities. In this study, we aimed to 
evaluate patterns of failure with this approach and assess 
whether size of lesion correlated with local failure. 
Materials and Methods: We retrospectively reviewed 30 
patients treated with CK to 33 lesions between 2011-2014. 
Both the cavity resection volume (GTV) and CK treatment 
volume (PTV) were analyzed on treatment planning MRI for 
all cases. Patterns of intracranial control were analyzed in 26 
patients with post-treatment imaging. Survival was estimated 
by the Kaplan Meier method and prognostic factors for local 
and distant control were examined with Fisher’s exact test. 
Results: The most common histologies were lung (42%), 
breast (21%), and melanoma (15%). The cohort was evenly 
split by gender and generally RPA I (33%) and RPA II (57%). 
Median preoperative diameter was 3.3cm and 57% of patients 
underwent gross total resection. Median cavity volume was 
17.5cm3 (range 2.4-69.8 cm3) and median treatment volume 
was 25.11cm3 (range 4.7-90.9cm3). Treatments were 
delivered to a median 30 Gy in 5 fractions to the 75% isodose 
line. Synchronous metastases were treated at the time of CK 
in 33% of cases. The median clinical follow up for the 13 
living patients was 16.9 months (range 4.4-35.2) and for the 
entire cohort of 30 patients was 9.5 months (range 1.0-34.3). 
Local failure developed in 7 treated cavities (23%) and 
median time to local failure was not reached. Patients with 
lung primaries were found to fail locally in five of twelve 
cases (42%) compared to two of 17 (12%) non lung histologies 
(p=0.092). Evaluation of both cavity volume and CK 
treatment volume at a variety of cut-off points showed no 
association with local failure and size (p>0.61 and 0.64, 
respectively). Distant brain failure occurred in 20 cases (63%) 
at a median of 4.6 months. Distant failure developed in eight 
of nine patients with synchronous metastases (89%) compared 
to 11 of 20 without synchronous metastases (56%) (p=0.107). 
Salvage therapies included WBRT (23%) performed at a 
median of 5.1 months from treatment and additional SRS 
(40%) at a median of 4.9 months from treatment. 
Leptomeningeal carcinomatosis developed in 12 cases (40%). 
Patients survived a median of 10.1 months from the time of 
treatment. 
Conclusions: This study suggests that large resection cavities 
are likely to achieve equivalent local control as smaller 
resection beds using adjuvant CK strategy. However, patients 
with lung primaries appear more likely to fail within this 
cohort. Most patients do develop intracranial failure which 
was correlated with synchronous metastases at the time of 
CK. The majority of patients with large cavity volumes were 
spared or delayed WBRT with the use of local CK therapy.  
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Purpose/Objective: The most common site of relapse in 
muscoloskeletal sarcomas is lung. Metastasectomy is 
considered the standard of care in these patients (pts). In 
those unfit for surgery SBRT might represent however an 
alternative approach. The purpose of this study is to evaluate 
local control and toxicity of SBRT in a group of pts treated for 
lung metastases (LM) from bone and soft tissue sarcomas. 
Materials and Methods: From October 2010 to July 2014, 24 
pts with LM from sarcomas not amenable to surgery were 
treated with daily cone beam CT guided SBRT. 22 of them 
had already been submitted at least once to thoracic surgery 
procedures, and 16 pts had been treated with several lines of 
chemotherapy. In 50% of pts the primary tumor was a soft 
tissue sarcoma and in 50% a bone sarcoma (Ewing sarcoma: 5 
pts; osteosarcoma: 3 pts; chondrosarcoma: 4 pts). 21% of pts 
had LM at diagnosis whereas 79% developed LM at a mean of 
39,9 months after initial diagnosis. 71 lesions were treated 
with SBRT. All patients underwent computed tomography 
simulation. Active breath control (ABC©) was employed to 
reduce internal margin in lesions located in the lower lobes. 
Dose was prescribed to 80% isodose. Administered dose 
ranged from 30 to 60 Gy in 3-8 fractions. Follow-up (fu) 
included physical examination and a chest CT scan +/- FDG 
PET/CT every 3 months after treatment. Response rates were 
